UPB
Upstream Bio, Inc.
Next earnings Aug 4, 2026 · consensus $-0.77 EPS, $435K rev
Last earnings +4.6% on 2026-05-13
$6.75
▲ +6.13%$6.75▼ -38.24%
over 1Y
L $5.92EODHDH $32.60
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.1%
1W+6.1%
1M-18.3%
3M-22.1%
YTD-75.1%
1Y-38.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Revenue grew 20.4% YoY; but unprofitable (net margin -5026.0%).
Revenue (FY2025) $2.85M · FY2025
Upstream Bio, Inc. shows $2.85M in FY2025 revenue (+20.4% YoY), a -5026.0% net margin, and -42.2% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $2.38M | $2.37M | $2.85M |
| Gross profit | — | — | — |
| Operating income | -$40.1M | -$77.8M | -$160M |
| Net income | -$20.5M | -$62.8M | -$143M |
| Diluted EPS | -$12.95 | -$5.58 | -$2.66 |
| Net margin | -862.9% | -2650.0% | -5026.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$266M
EV / EBITDA—
EV / Sales93.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-39.0%
FCF yield-36.3%
Quality & risk
ROIC (est.)-37.3%
Free cash flow-$133M
Total debt—
Net cash$102M
Altman Z-Score14.08 safe
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗8-KPeriod ending 2026-06-092026-06-10open ↗
Frequently asked
- Is Upstream Bio, Inc. (UPB) a buy?
- UPB currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 20.4% YoY; but unprofitable (net margin -5026.0%).
- What is Upstream Bio, Inc.'s quality score?
- UPB scores 39.23529411764706/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0002022626, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 4:54:35 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.